Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases of the CNS.
Taysha Gene Therapies is a leading biotechnology company dedicated to developing innovative gene therapies for severe monogenic diseases affecting the central nervous system. With a strong focus on transforming patient care, Taysha Gene Therapies is committed to addressing critical unmet medical needs and enhancing the quality of life for patients and their families.
Located in Dallas, TX, Taysha Gene Therapies leverages cutting-edge adeno-associated virus (AAV) technology to advance its clinical programs. The company’s primary address is in Dallas, TX, US, where its expert teams are focused on driving breakthroughs in gene therapy. Taysha Gene Therapies' lead program, TSHA-102, targets Rett syndrome, a rare neurodevelopmental disorder, reflecting the company’s dedication to pioneering treatments for challenging conditions.
Taysha Gene Therapies is driven by a vision of creating transformative medicines through advanced biotechnology. We invite the management of Taysha Gene Therapies to create a customized and exclusive company showcase and product listing on our platform, to further highlight their innovative work and commitment to advancing healthcare.
Taysha Gene Therapies est une entreprise biotechnologique de premier plan dédiée au développement de thérapies géniques innovantes pour les maladies monogéniques sévères affectant le système nerveux central. En mettant l'accent sur la transformation des soins aux patients, Taysha Gene Therapies s'engage à répondre aux besoins médicaux critiques non satisfaits et à améliorer la qualité de vie des patients et de leurs familles.
Située à Dallas, TX, Taysha Gene Therapies exploite une technologie de pointe de virus adéno-associés (AAV) pour faire progresser ses programmes cliniques. L'adresse principale de l'entreprise est à Dallas, TX, États-Unis, où ses équipes d'experts se concentrent sur la réalisation de percées dans la thérapie génique. Le programme phare de Taysha Gene Therapies, TSHA-102, cible le syndrome de Rett, une maladie neurodéveloppementale rare, reflétant l'engagement de l'entreprise à créer des traitements pionniers pour des affections difficiles.
Taysha Gene Therapies est animée par une vision de création de médicaments transformateurs grâce à la biotechnologie avancée. Nous invitons la direction de Taysha Gene Therapies à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme, afin de mettre en évidence davantage leur travail innovant et leur engagement à faire progresser les soins de santé.
Compare Taysha Gene Therapies with 3 companies in Biotechnology
| Comparison Field |
Taysha Gene TherapiesMain Company |
Cartesian Therapeuti...View Profile |
Maravai LifeSciencesView Profile |
Harba Solutions Inc.View Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 2016 | 2014 | 2021 |
|
Company Size
|
— | 11-50 | 501-1,000 | 201-500 |
|
City
|
Dallas, TX | Gaithersburg, MD | San Diego, California | Indianapolis, Indiana |
|
Country
|
United States | United States | United States | United States |
|
Skills & Keywords
Comparing with main company
|
8 Total Skills
Gene Therapy
Biotechnology
AAV Technology
Central Nervous System
Rett Syndrome
Monogenic Diseases
Pharmaceuticals
Molecular Biology
|
12 Total
12 Unique
Unique Skills:
ARDS
Autoimmune Diseases
Cancer Research
Cardiovascular Disease
Cell Therapy
Immunology
+6
|
18 Total
1 Common
17 Unique
Match
13%
Common Skills:
Biotechnology
Unique Skills:
Bioprocess Impurity Detection
CDMO Services
Custom Chemistry
DNA
Enzymes
Genomics
+11
|
15 Total
1 Common
14 Unique
Match
13%
Common Skills:
Biotechnology
Unique Skills:
CDMO
Cell Biology
Chemistry
Computational Biology
CRO
Life Sciences
+8
|
Other organizations in the same industry
This company is also known as